MOTS-c + SS-31 (Mitochondrial Stack)

MOTS-c and SS-31 are the two peptides people mean when they talk about "mitochondrial peptides," and they are often stacked. The appeal is that they act on the same organelle at two different levels. SS-31 works on the physical structure where ATP is made. MOTS-c works on the signals that tell the cell how to adapt its metabolism. Neither one duplicates the other. SS-31 is a four-amino-acid peptide (D-Arg-2',6'-dimethylTyr-Lys-Phe-NH2) from the Szeto-Schiller series developed at Cornell. It is the same molecule as elamipretide, sold by Stealth BioTherapeutics as Forzinity. This stack lists it as SS-31 because that is the name used in longevity and research-chemical circles. The elamipretide page covers the approved drug, its label, and how patients access it. SS-31 builds up at the inner mitochondrial membrane without depending on membrane potential, and there it binds cardiolipin. Cardiolipin is a phospholipid found only in mitochondria. It holds the electron transport chain complexes together in supercomplexes and keeps the folded cristae in shape. In Birk et al. (J Am Soc Nephrol 2013), SS-31 bound cardiolipin with high affinity, blocked the cytochrome c peroxidase activity that oxidizes cardiolipin, and protected cristae from ischemic damage. In short, SS-31 keeps the energy-producing machinery intact and efficient. MOTS-c is a 16-amino-acid peptide. Its gene sits inside the 12S rRNA region of mitochondrial DNA. Pinchas Cohen's and Changhan Lee's group at USC described it in 2015. MOTS-c activates AMPK, the cell's energy sensor, by acting on the folate-methionine cycle. It improves glucose handling and insulin sensitivity in mice and has been called an exercise mimetic. Kim et al. (Cell Metabolism 2018) showed that under metabolic stress MOTS-c moves into the nucleus and regulates nuclear genes, including antioxidant-response genes controlled with NRF2. That makes it a direct signaling line from the mitochondria to the nucleus. Reynolds et al. (Nature Communications 2021) found that exercise raises MOTS-c in human muscle and blood, and that giving MOTS-c three times a week to mice starting late in life (23.5 months) improved their physical capacity. The case for the stack follows from those two roles. MOTS-c pushes the cell toward an exercise-like adaptive state: more fatty-acid oxidation, better glucose uptake, and stress-responsive gene expression. That raises the workload on the electron transport chain. SS-31 aims to make that chain run with less electron leak and less cardiolipin damage while it carries the extra load. Put simply, MOTS-c changes the instructions and SS-31 protects the machinery that carries them out. The argument is mechanistically coherent and attractive. It is still an argument, not a measured result. Many protocols built around the queries "MOTS-c SS-31 NAD+" add an NAD+ precursor as an optional third component. That overlaps with our NAD+ / MOTS-c / 5-Amino-1MQ stack, which covers the NAD+ logic in detail. Of the three ingredients, NAD+ precursors such as NMN and NR have by far the most human trial data. If someone runs all three, NAD+ is the best-evidenced part, not a garnish.

The SS-31 side of the mechanism is about the quality of mitochondria, not their quantity. Cardiolipin is easily oxidized, and oxidized cardiolipin is an early sign of mitochondrial decline in aging and in ischemic injury. When cardiolipin is damaged, the cristae lose their shape, the respiratory supercomplexes come apart, and electrons leak to form reactive oxygen species. That leak damages more cardiolipin, so the problem feeds itself. SS-31 interrupts that loop. Campbell et al. (Free Radical Biology and Medicine 2019) gave aged mice (26 months) SS-31 for 8 weeks. It reversed the age-related drop in maximum mitochondrial ATP production and in the efficiency of oxidative phosphorylation, restored glutathione redox balance across the muscle proteome, and improved treadmill endurance. Mitochondrial protein content did not rise. The mitochondria worked better without there being more of them. The MOTS-c side is about signaling and adaptation. AMPK activation moves cells toward glucose uptake and fat oxidation and engages the PGC-1α program behind mitochondrial biogenesis. When MOTS-c moves into the nucleus under stress, it works with NRF2 on antioxidant-response genes, so the cell's own defenses rise. In aged mice, MOTS-c improved physical capacity and markers of muscle metabolism. In humans, exercise releases MOTS-c into the blood, which suggests it is part of how the body signals that it has trained. In theory, the combination covers both halves of mitochondrial fitness: the adaptive signal (MOTS-c) and the structural integrity of the membranes that carry the extra flux (SS-31). Each has improved endurance in old mice, but in separate experiments from separate labs. Nobody has measured whether their effects add up, overlap, or interfere. There is one real theoretical tension. Some of the benefit of exercise depends on short bursts of mitochondrial reactive oxygen species, a process called mitohormesis. In humans, high-dose antioxidant vitamins (vitamin C plus vitamin E) have blunted the insulin-sensitivity gains from training. SS-31 is not a classic antioxidant that mops up free radicals. It reduces how much reactive oxygen the mitochondria produce by keeping the electron transport chain intact. Whether that dampens the stress signals MOTS-c and exercise rely on is unknown. It is a reason to be skeptical of the idea that more mitochondrial support is always better.

No trial in humans or animals has tested MOTS-c and SS-31 together. A PubMed search as of October 2026 finds no study that gives both. The only paper that discusses both in depth is a 2026 Sports Medicine narrative review of peptides used in sports medicine (Mendias and Awan), which covers each separately. Any statement about what the stack does is an extrapolation from its components. SS-31 (elamipretide) has the larger human dataset, but almost all of it comes from rare-disease and cardiology trials, not healthy aging, and the record is mixed. On 19 September 2025 the FDA granted accelerated approval to elamipretide (Forzinity) for Barth syndrome in patients weighing at least 30 kg. The approval rested on improved knee-extensor muscle strength, an intermediate endpoint, so a confirmatory trial is required. Barth syndrome is a genetic disorder of cardiolipin remodeling, so the drug's mechanism fits the disease unusually well. Outside Barth syndrome, most of the major trials missed their primary endpoints. PROGRESS-HF in heart failure and EMBRACE-STEMI in acute heart attack were both negative. MMPOWER-3 in primary mitochondrial myopathy (Karaa et al., Neurology 2023) randomized 218 patients for 24 weeks and found no difference in six-minute walk distance (−3.2 m versus placebo, p = 0.69) or in total fatigue score. ReCLAIM-2 in dry age-related macular degeneration with geographic atrophy (Ehlers et al., Ophthalmology Science 2025) gave 176 patients 40 mg a day under the skin for 48 weeks and missed both primary endpoints, visual acuity in low light and growth of the atrophy area. A nominal signal on preservation of the ellipsoid zone, a retinal layer, became the primary endpoint of the Phase 3 ReNEW trial, which is fully enrolled and expected to report in late 2027. The closest thing to longevity-relevant human data for SS-31 is one trial in older adults (Roshanravan et al., PLoS One 2021). It enrolled 39 healthy people aged 60 to 85 with poorly functioning mitochondria. A single 2-hour IV infusion raised muscle ATP production capacity on the day of treatment, a borderline result (p = 0.055 for the absolute change, 0.045 for the percentage change). The effect was gone by day 7, and there was no improvement in fatigue resistance. Stealth funded the study. MOTS-c has minimal human evidence. What exists is observational: blood MOTS-c levels track insulin sensitivity, obesity, and exercise. No trial of native MOTS-c in humans has been published, and there is no human pharmacokinetic data. The nearest thing is CB4211, a modified MOTS-c analog from CohBar and a different molecule. In 2021 CohBar announced a 4-week Phase 1b in 20 adults with obesity and fatty liver disease, reporting lower liver enzymes and glucose, through a press release and a conference poster, not a peer-reviewed paper. Some mechanistic findings also point the other way. In 2026, researchers from the same network that discovered MOTS-c reported that exposing human mesenchymal stromal cells to MOTS-c activated AMPK but increased senescence markers and weakened the cells' ability to repair tissue in a mouse kidney model. Both peptides improve physical capacity in aged mice, both have coherent mechanisms, and neither has shown a benefit in healthy aging humans. The stack is a reasonable mechanistic hypothesis built from one drug with a narrow approval and a long list of failed trials, and one peptide with essentially no interventional human data.

No combined protocol has been clinically validated. The numbers below are what longevity and peptide communities commonly discuss, anchored to clinical or preclinical data where any exists. They are not a recommendation. Anyone considering this stack should do so under the supervision of a clinician who can review their medications, run baseline labs, and judge whether research-grade peptides are appropriate at all. SS-31: the only well-characterized human dose is the one from the disease trials and the Forzinity label, 40 mg once daily by subcutaneous injection. Community protocols for research-chemical SS-31 vary widely in dose, frequency, and cycle length. None is based on a dose-finding or pharmacokinetic study in healthy adults. In practice, people using SS-31 for longevity are using research-grade peptide, not the GMP-manufactured drug, which is distributed through a manufacturer-controlled specialty pharmacy for Barth syndrome. MOTS-c: the most commonly described pattern in research-chemical channels is 5–10 mg subcutaneously two to three times per week, often timed around training to match the natural rise after exercise. The intermittent schedule loosely follows the three-times-weekly dosing in the aged-mouse work. There is no human dose-finding study, so any specific dose is an extrapolation. Cycles of 4–12 weeks followed by breaks are commonly discussed but have no clinical basis. The usual community pattern runs daily SS-31 alongside intermittent MOTS-c over the same 4–12 week block. A more cautious approach starts one peptide at a time and adds the second after a couple of weeks, so that any benefit or side effect can be traced to its source. Commonly suggested baseline and follow-up labs, tracked with a clinician, are fasting glucose and insulin, HbA1c, a lipid panel, liver enzymes, and a CBC. MOTS-c is expected to lower glucose, so this matters most for anyone on glucose-lowering medication. Adding NAD+: the most-studied option is an oral precursor. NMN at 250–600 mg/day is the range used in most human trials. Injectable or IV NAD+ is a different intervention with its own considerations. Our NAD+ / MOTS-c / 5-Amino-1MQ stack page covers NAD+ dosing in detail.